Drug Profile

Research programme: oral peptides - Aquestive Therapeutics

Alternative Names: Exenatide buccal delivery - Aquestive Therapeutics

Latest Information Update: 10 Apr 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MonoSol Rx
Developer Aquestive Therapeutics
Class Peptides
Mechanism of Action Glucagon-like peptide-1 receptor agonists; Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 Apr 2018 Discontinued - Preclinical for Undefined indication in USA (Buccal) (Aquestive Therapeutics pipeline, April 2018)
01 Apr 2015 Preclinical trials in Undefined indication in USA (Buccal)
20 Dec 2012 MonoSol Rx has patent protection for PharmFilm^® drug delivery technology in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com